Dr. Markus Glatzer
Department of Radiation Oncology · Dept. IV
EORTC 1901-LCG PRIMALung Study
Jan 3, 2022PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study)
Clinical Studies - Jan 3, 2022 - Nov 3, 2030
Scheduled
Project leader: Putora Paul Martin
Members: Patzl Sigrid, Glatzer Markus
Role of Brachytherapy in the post-operative management of endometrial cancer: decision-making analysis among European experts“
Feb 4, 2021To better understand decision-making processes for postoperative brachytherapy in endometrial cancer we want to initiate a project using an approach developed in our institution (objective consensus methodology) among European experts for this indica...
Clinical Studies - Feb 4, 2021 - Oct 31, 2021
Automatically Closed
Project leader: Glatzer Markus
Checkmate 73L (CA20973L)
Jan 1, 2020A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally A...
Clinical Studies - Jan 1, 2020 - Dec 11, 2023
Ongoing
Members: Glatzer Markus
DOSIS RCT_Dose-intensified-Image-guided Fractionatet Stereotactic Body Radiation Therapy for Painful Spinal Metastasis versus Conventional Therapy: A Randomized Controlled Trial
Jul 3, 2019Primary Objective: Randomised arm: To compare Long-term pain Response after dose- intensified imageguide hypofractioned SBRT employing SIB versus conventional Radiation therapy for painful spinal metastasis Prospective observational arm: To assess t...
Clinical Studies - Jul 3, 2019 - Jul 3, 2024
Ongoing
Project leader: Henke Guido
Members: Panje Cédric, Glatzer Markus
EORTC 1702-LCG-ROG Targeted therapy with or without dose-intensified radiotterapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors
Jun 12, 2019Targeted therapy beyond Progression with or without dose-intensified radiotHerapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors (HALT) Objectives: To determine wether in patients with Mutation positive advanced NSCLC the use of...
Clinical Studies - Jun 12, 2019 - Feb 1, 2021
Automatically Closed
Project leader: Glatzer Markus